Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/ refractory aggressive B-cell non-Hodgkin lymphoma by Dang, Nam H. et al.
Randomized, phase 3 trial of inotuzumab ozogamicin plus 
rituximab versus chemotherapy plus rituximab for relapsed/
refractory aggressive B-cell non-Hodgkin lymphoma
Nam H. Dang1, Michinori Ogura2,3, Sylvie Castaigne4, Luis E. Fayad5, Mats Jerkeman6, 
John Radford7, Antonio Pezzutto8, Igor Bondarenko9, Douglas A. Stewart10, Michael 
Shnaidman11, DR. Sharon Sullivan11, Erik Vandendries11, Kensei Tobinai12, Radhakrishnan 
Ramchandren13, Paul A. Hamlin14, Eva Giné15, and Kiyoshi Ando16
1University of Florida, Gainesville, FL, USA
2Nagoya Daini Red Cross Hospital, Nagoya, Japan
3Tokai Central Hospital, Kakamigahara, Japan
4University of Versailles Saint-Quentin, Le Chesnay, France
5University of Texas MD Anderson Cancer Center, Houston, TX, USA
6Lund University, Lund, Sweden
7University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health 
Science Centre, Manchester, UK
8Charité-Universitätsmedizin, Berlin, Germany
9State Medical Academy, Dnepropetrovsk, Ukraine
10University of Calgary, Calgary, AB, Canada
Correspondence: Professor N H Dang, Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road, Gainesville, 
FL 32610, USA, Tel: +1 352-273-9103, Fax: +1 352-273-5006, Nam.Dang@medicine.ufl.edu.
Author contributions:
NHD, MO, SC, LEF, MJ, JR, AP, IB, DAS, KT, RR, PAH, EG and KA participated in the collection, interpretation and analysis of 
data and the development of the manuscript draft. MS, SS and EV participated in study design, the interpretation and analysis of data 
and the development of the manuscript
Author disclosure information:
NHD has received research funding from Pfizer, Eisai, Valor, Pharmacyclics, Seattle Genetics, and Oncomed.
MO has served as a consultant/advisor for Mundipharma, MeijiSeika Pharma, and Celgene, and has received research funding from 
SymBio.
SC has received honoraria and research funding and travel/accommodation expenses from, and served as a consultant/advisor for 
Pfizer.
LEF, MJ, and IB have no relevant relationships to disclose.
JR has served as a consultant/advisor for Takeda and received honoraria from Takeda and Seattle Genetics.
AP has served as a consultant/advisor for Novartis, Celgene, Roche, Gilead, Janssen.
DAS has served as a consultant/advisor for Lundbeck.
MS, SS, and EV are employees of and own stock in Pfizer.
KT has received research funding from Celgene.
RR has received research funding from, and is a member of a speakers bureau for Seattle Genetics.
PAH has served as a consultant/advisor for Genentech, Roche, Celgene, Portola and has received research funding from Spectrum, 
Portola, Molecular Templates, Novartis, GSK, and Seattle Genetics.
EG has received research funding from Janssen.
KA has received research funding from Kyowa Hakko Kirin.
HHS Public Access
Author manuscript
Br J Haematol. Author manuscript; available in PMC 2019 August 01.
Published in final edited form as:
Br J Haematol. 2018 August ; 182(4): 583–586. doi:10.1111/bjh.14820.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
11Pfizer Inc, Cambridge, MA, USA
12National Cancer Centre Hospital, Tokyo, Japan
13Karmanos Cancer Center, Detroit, MI, USA
14Memorial Sloan Kettering Cancer Center, New York, NY, USA
15Hospital Clínic, Barcelona, Spain
16Tokai University, School Medicine, Isehara, Kanagawa, Japan
Keywords
inotuzumab ozogamicin; B-cell non-Hodgkin lymphoma; CD22+; antibody-drug conjugate; 
rituximab
Inotuzumab ozogamicin (InO), a humanized anti-CD22 antibody–calicheamicin conjugate, 
demonstrated preliminary antitumour activity and manageable toxicity in phase 1/2 trials for 
the treatment of relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), as a 
single-agent (Advani et al, 2010; Ogura et al, 2010) and in combination with rituximab (R-
InO) (Advani et al, 2010; Fayad et al, 2013; Ogura et al, 2012; Ogura et al, 2010). Given this 
preliminary evidence, a 2-arm, randomized, open-label, phase 3 study (NCT01232556) was 
conducted to compare the efficacy and safety of R-InO with investigator’s choice (IC) of 
rituximab plus bendamustine (R-B) or rituximab plus gemcitabine (R-G), in adults with R/R 
CD20+/CD22+ aggressive B-NHL who were not candidates for high-dose chemotherapy, 
with or without transplant (see Supplemental Methods and Table SI for eligibility criteria, 
dose regimens and dose-delay/-reduction criteria).
The primary endpoint was overall survival (OS); 2 interim analyses (IAs) were planned 
when 40% and 70% of OS events were reached (see Supplemental Methods for details of 
assessments and statistical methods). The trial was to be terminated for futility if P>0.29 
(hazard ratio [HR]>0.9) or P>0.10 (HR>0.82) at the first or second IA, respectively, or if 
P<0.0073 for efficacy at the second analysis. The planned IA based on ~40% of OS events 
(108 events) conducted in May 2013 yielded an estimated HR>0.9 for OS in the R-InO 
versus IC arm; enrollment was thus stopped for futility. Reported here are the final data from 
this trial (locked on 24 July 2014) to inform future research and potential clinical studies in 
this difficult-to-treat patient population.
Patient enrollment occurred between February 2011 and May 2013; 338 patients were 
randomized (R-InO, n=166; IC, n=172 [R-B, n=137; R-G, n=35]; Fig S1). Nearly all 
patients (91%) had diffuse large B-cell lymphoma (DLBCL) at baseline; 68% were aged ≥65 
years (Table SII). Age was the primary reason why enrolled patients were not candidates for 
high-dose chemotherapy (R-InO, 77%; IC, 67%; Table SIII). Threehundred and thirty-two 
patients received ≥1 dose of study drug [median (range) number of treatment cycles: 3.0 
(1.0–6.0) for R-InO and R-G, 3.5 (1.0–6.0) for R-B; Table SIV]. Ninety-four patients 
completed treatment. Common reasons for discontinuing were progressive disease/relapse 
(R-InO, 50% vs IC, 57%) and adverse events (AEs; R-InO, 32% vs IC, 17%; Table SV). 
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Median (range) duration of follow-up among surviving patients was 14.9 (0.4–32.8) months 
for R-InO and 15.9 (0.1–31.2) months for IC.
Overall survival was not significantly different for R-InO versus IC (P=0.708; HR [95% 
confidence interval (CI)]=1.1 [0.8–1.4]; Fig S2); Kaplan-Meier estimated median (95% CI) 
OS was 9.5 (7.0–14.5) and 9.5 (7.7–14.1) months (estimated probabilities of OS [95% CI] at 
18 months, 35% [27%–43%] and 37% [29%–45%]). Progression-free survival (PFS) was 
also not significantly different for R-InO versus IC (P=0.27; HR [95% CI)]=0.9 [0.7–1.2]; 
Fig S2). Median (95% CI) PFS with R-InO and IC were 3.7 (2.9–5.0) and 3.5 (2.8–4.9) 
months (estimated probabilities of PFS [95% CI] at 18 months, 19% [13%–26%] and 17% 
[12%–24%]). Notably, survival among patients receiving R-InO was prolonged for those 
with higher versus lower baseline CD22 expression levels (Fig S3). Among all randomized 
patients, the objective response rate (ORR; 95% CI) was 41% (33%–49%) for R-InO and 
44% (36%–51%) for IC (arm difference, 3% [–8% to 13%]; P=0.714; Table I); Kaplan-
Meier estimated median (95% CI) duration of response (DOR) for R-InO versus IC was 11.6 
(7.8–not reached [NR]) versus 6.9 (5.5–10.8) months (HR=0.76 [0.47–1.25]; P=0.142).
Median OS and PFS with R-InO were 9.5 [95% CI, 7.0–14.5] and 3.7 [2.9–5.0] months, 
respectively; ORR and DOR were 41% and 11.6 months. Although comparisons across 
studies require caution due to differences in design and patient characteristics, median OS 
and PFS with R-InO in the previous study with refractory aggressive B-NHL (n=30) are 
shorter (OS, 8.8 [3.9–NR] months; PFS, 1.9 [1.0–4.8] months), the ORR is lower (20%), and 
the DOR is shorter (6.1 months) (Fayad et al, 2013). Conversely, the median OS and PFS 
with R-InO in the relapsed DLBCL cohort in the previous study (n=47) are longer (OS, NR 
[34.7–NR] months; PFS, 17.1 [7.8–NR] months), the ORR is higher (74%), and the DOR is 
longer (17.7 months) (Fayad et al, 2013).
The observed toxicity profile of R-InO is generally consistent with that reported previously 
for InO alone (Advani et al, 2010; Ogura et al, 2010) and for R-InO (Fayad et al, 2013; 
Ogura et al, 2012).Treatment-related grade ≥3 treatment-emergent AEs (TEAEs) differing 
by ≥10% of patients between treatment arms were hematologic (Table II). All-cause TEAEs 
followed a similar pattern (Table SVI). Most common serious AEs (>5 patients in either 
arm) included febrile neutropenia (n=5 vs 7) and pneumonia (n=8 vs 1). Two treatment-
related deaths occurred between treatment start and 56 days after last dose (R-InO, 
pneumonia [n=1]; IC, fungal pneumonia, febrile neutropenia and septicaemia [n=1]). 
Permanent discontinuations due to AEs were more frequent with R-InO versus IC (25% vs 
18%), most commonly due to thrombocytopenia in the R-InO arm (Table SVII).
Treatment-related hepatic TEAEs were more frequent with R-InO versus IC, with 
hyperbilirubinaemia occurring in 8% versus 2% of patients (Table II). Two patients had 
grade 3 veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) during R-InO 
treatment (1 after the maximum 6 R-InO cycles; 1 after 3 cycles, resulting in treatment 
discontinuation). One additional patient developed VOD/SOS approximately 13 months 
after receiving a single R-InO dose and multiple subsequent therapies, including allogeneic 
stem cell transplantation after the single R-InO dose and before VOD/SOS onset. No 
VOD/SOS events occurred in the IC arm.
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Rituximab-InO treatment was associated with antitumour activity in patients with R/R 
aggressive B-NHL who were not candidates for high-dose chemotherapy, with or without 
transplant, for whom treatment options are limited. However, R-InO was not superior to IC 
with respect to OS; estimates of ORR and median PFS and OS were similar for the 2 
treatments. Nevertheless, the efficacy observed here and in other studies (Fayad et al, 2013; 
Ogura et al, 2016) suggests an examination of InO-containing combination therapies may be 
appropriate in certain patient populations. A study of InO plus rituximab, 
cyclophosphamide, vincristine and prednisolone in chemotherapy-naïve patients with 
DLBCL who are not candidates for anthracycline-based treatment is currently recruiting 
(NCT01679119).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table II.
Treatment-related, treatment-emergent AEs occurring in >10% of patients in either R-InO or IC arm.
R-InO (n=164) IC (n=167)
Any grade Grade ≥3 Any grade Grade 3/4
Any AE, n (%) 148 (90) 102 (62) 146 (87) 107 (64)
 Thrombocytopenia 99 (60) 78 (48) 59 (35) 26 (16)
 Neutropenia 57 (35) 40 (24) 79 (47) 67 (40)
 Fatigue 38 (23) 5 (3) 31 (19) 1 (1)
 Nausea 39 (24) 0 25 (27) 0
 AST increased 43 (26) 7 (4) 15 (9) 4 (2)
 Pyrexia 16 (10) 1 (1) 20 (12) 2 (1)
 Constipation 18 (11) 0 14 (8) 0
 GGT increased 31 (19) 7 (4) 8 (5) 0
 Leucopenia 35 (21) 13 (8) 52 (31) 39 (23)
 ALT increased 28 (17) 7 (4) 13 (8) 2 (1)
 Decreased appetite 20 (12) 2 (1) 24 (14) 0
 Lymphopenia 26 (16) 15 (9) 38 (23) 37 (22)
 Anaemia 17 (10) 7 (4) 39 (23) 12 (7)
 Blood ALP increased 22 (13) 1 (1) 9 (5) 1 (1)
 Cough 4 (2) 0 5 (3) 1 (1)
 Vomiting 14 (9) 0 22 (13) 0
 Diarrhoea 10 (6) 0 17 (10) 1 (1)
AE=adverse event; ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; GGT=gamma-glutamyl 
transferase; IC=investigator’s choice (rituximab plus bendamustine or rituximab plus gemcitabine); R-InO=inotuzumab plus rituximab.
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